echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > SMC approves the first immunotherapy combination (Nivolumab combined with ipilmumab) for patients with rare-mutated advanced colorectal cancer

    SMC approves the first immunotherapy combination (Nivolumab combined with ipilmumab) for patients with rare-mutated advanced colorectal cancer

    • Last Update: 2021-12-24
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Nivolumab combined with ipilmumab has been approved by the Scottish Medicines Federation (SMC) as a treatment option for adult patients for the treatment of patients who have failed previous fluoropyrimidine-based chemotherapy


    Recently, Bristol-Myers Squibb (BMS) announced that the Scottish Pharmaceutical Union (SMC) has accepted Nivolumab in combination with ipilmumab as a late mismatch repair defect (dMMR) or high microsatellite instability (MSIH)Treatment options for adults with colorectal cancer , these patients have failed previous fluoropyrimidine-based chemotherapy, and the therapy is used by the NHS in Scotland


    Colorectal cancer

    This group of patients is characterized by a rare genetic mutation called MSI-H or dMMR, which affects how the cancer grows


    diagnosis

    The median age of the treated patients was 66 years (N = 45)


    The objective response rate and disease control rate were 69% (95% CI, 53 to 82) and 84% (95% CI, 70.


     

    Original source:

    Original source:

    https:// href="https://" target="_blank" rel="noopener">https:// https://


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.